Elanco Animal Health (NYSE:ELAN) Issues Q2 2026 Earnings Guidance

Key Points

• Elanco issued Q2 2026 guidance of $0.250–$0.285 EPS, below the consensus of $0.290, while revenue guidance was in line at $1.3 billion, and it updated FY 2026 EPS guidance to $1.030–$1.090.
• The stock gained about 2.4% to open at $23.05 after the update; this follows a recent quarter where Elanco beat estimates with $0.40 EPS (vs. $0.34 est.) and $1.37 billion revenue (vs. $1.28B est.).
• Sell-side sentiment is largely positive with a consensus rating of "Moderate Buy" and an average target of $27.90, and several firms have raised price targets to around $30.

Elanco Animal Health (NYSE:ELAN - Get Free Report) issued an update on its second quarter 2026 earnings guidance on Wednesday morning. The company provided EPS guidance of 0.250-0.285 for the period, compared to the consensus EPS estimate of 0.290. The company issued revenue guidance of $1.3 billion-$1.3 billion, compared to the consensus revenue estimate of $1.3 billion. Elanco Animal Health also updated its FY 2026 guidance to 1.030-1.090 EPS.

Elanco Animal Health Stock Up 2.4%

Elanco Animal Health stock opened at $23.05 on Wednesday. The company has a market capitalization of $11.46 billion, a P/E ratio of -48.02, a P/E/G ratio of 2.87 and a beta of 1.69. The firm's fifty day simple moving average is $23.82 and its 200-day simple moving average is $23.29. The company has a current ratio of 2.17, a quick ratio of 1.08 and a debt-to-equity ratio of 0.60. Elanco Animal Health has a 1-year low of $9.42 and a 1-year high of $27.72.

Elanco Animal Health (NYSE:ELAN - Get Free Report) last posted its earnings results on Wednesday, May 6th. The company reported $0.40 earnings per share (EPS) for the quarter, beating analysts' consensus estimates of $0.34 by $0.06. Elanco Animal Health had a negative net margin of 4.92% and a positive return on equity of 7.16%. The business had revenue of $1.37 billion for the quarter, compared to analyst estimates of $1.28 billion. Elanco Animal Health has set its Q2 2026 guidance at 0.250-0.285 EPS and its FY 2026 guidance at 1.030-1.090 EPS. Sell-side analysts forecast that Elanco Animal Health will post 1.03 earnings per share for the current fiscal year.

Analysts Set New Price Targets

Several research firms have issued reports on ELAN. Citigroup began coverage on shares of Elanco Animal Health in a research report on Wednesday, April 15th. They issued a "buy" rating and a $30.00 price target on the stock. Piper Sandler upgraded shares of Elanco Animal Health from a "neutral" rating to an "overweight" rating and raised their price target for the stock from $24.00 to $30.00 in a research report on Thursday, January 22nd. Morgan Stanley raised their price target on shares of Elanco Animal Health from $22.00 to $24.00 and gave the stock an "equal weight" rating in a research report on Wednesday, February 25th. Weiss Ratings upgraded shares of Elanco Animal Health from a "sell (d)" rating to a "sell (d+)" rating in a research report on Monday, April 27th. Finally, Leerink Partners raised their price target on shares of Elanco Animal Health from $26.00 to $30.00 and gave the stock an "outperform" rating in a research report on Tuesday, February 24th. One research analyst has rated the stock with a Strong Buy rating, nine have issued a Buy rating, two have assigned a Hold rating and one has assigned a Sell rating to the company. Based on data from MarketBeat.com, the stock presently has a consensus rating of "Moderate Buy" and an average target price of $27.90.

Hedge Funds Weigh In On Elanco Animal Health

A number of hedge funds and other institutional investors have recently made changes to their positions in the business. Parallel Advisors LLC lifted its holdings in shares of Elanco Animal Health by 5.9% during the 4th quarter. Parallel Advisors LLC now owns 7,060 shares of the company's stock worth $160,000 after acquiring an additional 392 shares during the period. Lazard Asset Management LLC lifted its holdings in shares of Elanco Animal Health by 0.6% during the 4th quarter. Lazard Asset Management LLC now owns 72,065 shares of the company's stock worth $1,631,000 after acquiring an additional 425 shares during the period. Meeder Advisory Services Inc. lifted its holdings in shares of Elanco Animal Health by 4.8% during the 4th quarter. Meeder Advisory Services Inc. now owns 11,235 shares of the company's stock worth $254,000 after acquiring an additional 510 shares during the period. NewEdge Advisors LLC lifted its holdings in shares of Elanco Animal Health by 133.7% during the 4th quarter. NewEdge Advisors LLC now owns 1,096 shares of the company's stock worth $25,000 after acquiring an additional 627 shares during the period. Finally, Arkadios Wealth Advisors lifted its holdings in shares of Elanco Animal Health by 1.2% during the 4th quarter. Arkadios Wealth Advisors now owns 52,868 shares of the company's stock worth $1,196,000 after acquiring an additional 652 shares during the period. 97.48% of the stock is owned by institutional investors.

About Elanco Animal Health

Elanco Animal Health Inc is a global leader in animal health dedicated to improving food and companion animal well-being. The company develops, manufactures and markets a range of products, including parasiticides, vaccines, antibiotics and feed additives designed to prevent and treat disease in livestock and pets. Elanco's portfolio spans both food-producing animals—such as cattle, swine, poultry and aquaculture—and companion animals, with offerings that support parasite control, pain management and infectious disease prevention.

Originally founded as the animal health division of Eli Lilly and Company in the mid-20th century, Elanco was spun off into an independent publicly traded company in 2018.

This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest reporting and unbiased coverage. Please send any questions or comments about this story to contact@marketbeat.com.